A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

India is witnessing a shift in its disease landscape. While greater awareness, improved hygiene and national health policies have helped curb communicable and preventable diseases, the country is now facing a growing burden of metabolic conditions such as fatty liver and colorectal cancer, alongside persistent infections including Helicobacter pylori and intestinal worm infestations, health experts said.

The concerns come ahead of the World Congress of Gastroenterology (WCOG) 2026, to be held in India for the first time from September 30 to October 3 at Yashobhoomi, Dwarka, under the theme “Transforming Gastrointestinal Health, Preserving Nature.”

Fatty Liver a Major Concern

Fatty liver disease has emerged as a key metabolic health challenge in India. An AIIMS-led systematic review and meta-analysis found the condition in 38.6 per cent of Indian adults and 35.4 per cent of children. It is closely associated with diabetes, obesity and hypertension and can remain silent until liver damage progresses.

A recent study found that one in four patients with type 2 diabetes has clinically significant fibrosis.

“India is facing an epidemiological shift at this time. We have made significant strides in controlling preventable disease through awareness, vaccinations and improving quality of life, however alongside these we are now seeing metabolic disease on a scale we have never handled before,” said Dr. Pramod Garg, Professor and Head, Department of Gastroenterology and Human Nutrition, AIIMS, New Delhi.

“Fatty liver is the clearest example. The disease is easy to find if we look for it, and we become aware only after the patient falls ill. This is a greater challenge than before—we must move away from only treating diseases—we must now actively promote good health,” he added.

To address the rising burden, India included fatty liver disease in its National Programme for Prevention and Control of Non-Communicable Diseases in 2021, followed by guidelines for its detection at the primary-care level.

Colorectal Cancer Cases Growing Among Young

The experts also flagged colorectal cancer as a growing concern, with cases increasingly being seen among younger adults. India recorded 40,430 new cases among men and 24,433 among women in 2022.

“India has never been short of gastroenterologists or technology. What we have lacked is the habit of taking early symptoms seriously. We often misattribute our symptoms to stress or simply overlook them,” said Dr. Govind Makharia, Professor, Department of Gastroenterology and Human Nutrition, AIIMS, New Delhi.

“Every time we fail to identify a disease early, we lose the opportunity to potentially modify its natural history. Any symptom that persists beyond two to three weeks should be evaluated,” he added.

Persistent Infections and Chronic Gut Diseases

H. pylori remains widespread and is associated with peptic ulcer disease and gastric cancer. Intestinal worm infections continue to affect children and can contribute to anaemia and undernutrition.

Chronic gastrointestinal conditions such as celiac disease and inflammatory bowel disease (IBD) are also increasingly being recognized in India. Community-based research led by AIIMS found celiac disease in approximately one in 96 people in northern India.

Dr. Vineet Ahuja, Professor, Department of Gastroenterology and Human Nutrition, AIIMS, New Delhi, said conditions such as IBD and celiac disease, once considered rare in India, are now regularly encountered in clinical practice.

“Advances in endoscopy, artificial intelligence and microbiome research are improving diagnosis and treatment. The challenge now is to make these advances more widely accessible,” he said.

“With the advent of AI, we potentially stand at a new era of medicine—we must not dismiss it, but learn to adapt to it and improve the quality of care we provide to our patients,” he added.

The experts stressed the importance of early detection and urged people not to ignore persistent gastrointestinal symptoms, blood in the stool, unexplained weight loss or sustained changes in bowel habits. Earlier testing and preventive interventions can help identify and manage several GI conditions before they progress

Researchers in the Netherlands are exploring a possibility to reach into remote, difficult areas in the brain without an open surgery. They have developed a tiny, screw-shaped robot that can move through brain tissue under the control of a magnet placed outside the body.

The method is yet to be tested on humans. They used sheep brain tissue, including a model in which blood was pumped through the brain's vessels to more closely mimic a living brain.

In laboratory experiments, the robot successfully travelled through real sheep brain tissue, offering an early glimpse of a less invasive way to reach areas that are difficult to access with conventional surgery.

The technology could eventually be useful to treat deep brain tumours, blood clots following stroke and vascular abnormalities.

How Does The Tiny Robot Work?

Scientists have made the robot in a spiral, screw-like shape. It does not have a conventional motor inside it. Instead, researchers control it using a rotating magnetic field generated outside the body. As the magnet rotates, the robot moves with it. Its screw-shaped body converts that rotation into forward movement, allowing it to drill its way through soft brain tissue.

The researchers also created a mathematical model to predict when the robot could lose synchronisation with the magnetic field. Simply making the magnet spin faster does not mean the robot will keep moving faster.

“Push a magnetic robot too fast and it simply stops listening to the magnet,” said Ewout Ligtenberg, first author of the study. He added, “We can now predict exactly when that happens, for any tissue, from a single test. That takes out a lot of guesswork when designing robots for the brain.”

Also read: Fifth Universal Definition of Myocardial Infarction: What the 3 New Heart Attack Categories Mean

Navigating Inside A Brain Is Not Easy

One of the biggest challenges of brain surgery is that is that brain tissue is soft, delicate and mechanically complex. The researchers initially tested their robot in gelatin before moving to actual sheep brain tissue.

In the sheep tissue, the robot remained synchronised with the magnetic field up to about 1.8 rotations per second when there was no blood flow. But once blood was pumped through the vessels, it fell to below 0.45 rotations per second. In other words, making the conditions that resemble a living brain made the robot harder to control.

The robot moved through the brain tissue at around 0.2 millimetres per second. When researchers reversed it, it was able to travel back through the pathway it had already created much faster, at about 2.9 millimetres per second.

Also read: New AI Tool Reads ECG In 2 Seconds, Detects Up To 90% Of Heart Valve Disease Cases

This May Help With Brain Lesions

The technology may have applications in treating brain lesions as some lesions sit deep inside the brain, where reaching them can mean passing through healthy tissue or opening the skull.

The researchers are look for a futuristic approach in which the tiny robot could potentially be guided through blood vessels to a location near the target, pass through the artery wall and then travel through brain tissue towards the lesion.

The robot has not been used to treat a brain tumour, remove a clot or operate on a person. Despite promising outcome, there are still major questions around safety, navigation, bleeding, tissue damage.

India has the medical expertise and infrastructure to perform significantly more corneal transplants, but a shortage of suitable donor corneas continues to leave thousands of patients waiting for treatment.

While an estimated 1 lakh corneal transplants are needed annually, only 25,000–30,000 are performed, meeting just 25–30% of the estimated need, said health experts as part of the 41st National Eye Donation Fortnight.

The shortage is also reflected in the availability of suitable donor tissue. In 2023–24, more than 49,000 corneas were retrieved in India, but only around 27,394 were considered suitable for transplantation.

Why Corneal Transplants Matter

Corneal blindness is a significant cause of treatable vision loss in India. “There is too much burden of corneal blindness in India, which is a leading cause of treatable blindness. Almost 1.1 to 1.3 million people are affected because of this corneal blindness,” said Dr Anita Gangar, Consultant Corneal Transplant Surgeon, Eye Department, Sir Ganga Ram Hospital, in a video posted on X.

The cornea is the transparent front surface of the eye that allows light to enter. When it becomes damaged, scarred or opaque, vision can be severely affected.

A corneal transplant replaces the damaged cornea with clear donor tissue, helping restore the eye’s optical pathway and vision.

Also read: World’s First Live AI-Assisted Brain Surgery Saves Patient’s Sight: How Does The Technology Work?

Common Causes of Corneal Blindness

• Corneal infections
• Eye trauma
• Surgery-related complications
• Hereditary conditions

Why Timely Eye Donation Matters

The availability of donor tissue remains a major constraint despite advances in corneal surgery.

“Corneal blindness is among the significant causes of vision loss that can potentially be treated through transplantation, yet thousands of patients continue to face a long and uncertain wait for suitable donor tissue,” said Padma Shri Prof. Dr Jeevan Titiyal, Regional Head – Clinical Services, Dr Agarwals Eye Hospital, at a press conference held in New Delhi.

The experts added that increasing eye donation requires not only greater public awareness but also stronger retrieval systems, efficient eye-bank networks and better coordination between hospitals and eye banks.

Timely retrieval is particularly important for preserving donor corneal tissue. Families are encouraged to contact an eye bank as soon as possible after the death of a loved one, with retrieval generally targeted within approximately six hours under appropriate conditions.

Read More: Diabetics Must Undergo Retinal Screening To Protect Eye Health: AIIMS Doctors

Eye Donation: Myths vs Facts

Myth: Diabetes or high blood pressure prevents eye donation.

Fact: These conditions do not automatically rule out donation. The medical team assesses tissue suitability after death.

Myth: Eye donation will disfigure the face.

Fact: Corneal retrieval is performed respectfully by trained professionals and does not cause visible facial disfigurement.

Myth: People who wear spectacles cannot donate their eyes.

Fact: Wearing spectacles or contact lenses does not automatically prevent donation. Eligibility is determined after death.

Myth: Only young people can donate.

Fact: People of different ages may be eligible, depending on the suitability of the donated tissue.

Advances in Corneal Transplantation

Corneal transplantation has evolved from conventional full-thickness procedures to more selective, layer-specific techniques. In suitable cases, surgeons can replace only the affected portion of the cornea, allowing for more targeted treatment and faster visual rehabilitation.

“Advances in corneal surgery now allow us to treat specific layers of the cornea, offering more targeted treatment and faster visual rehabilitation for appropriately selected patients. However, these advances can translate into better outcomes only when suitable donor tissue is available,” said Dr Prabjot Kaur, Senior Consultant Ophthalmologist, Dr Agarwals Eye Hospital.

41st National Eye Donation Fortnight

The 41st National Eye Donation Fortnight is being observed from 25 August to 8 September 2026. The 15-day nationwide awareness campaign, observed in India since 1985, aims to encourage eye donation and help bridge the gap between the demand for and availability of donor corneas.